<DOC>
	<DOCNO>NCT01129349</DOCNO>
	<brief_summary>To evaluate safety tolerability Oprozomib patient advance refractory recurrent solid tumor include determination Dose Limiting Toxicity ( DLT ) Maximum Tolerated Dose ( MTD ) To determine pharmacokinetics ( PK ) Oprozomib To explore anti-tumor activity Oprozomib patient population include overall response rate ( ORR ) , duration response ( DOR ) , progression-free survival ( PFS ) time progression ( TTP ) To define pharmacodynamics ( PDn ) Oprozomib .</brief_summary>
	<brief_title>Phase 1 Study Oprozomib Administered Orally Patients With Advanced Refractory Recurrent Solid Tumors</brief_title>
	<detailed_description>This Phase 1 , open label , dose-escalation study determine safety , MTD , PK/PDn Oprozomib administer orally ( PO ) Days 1 , 2 , 3 , 4 , 5 14 day cycle patient advance refractory recurrent solid tumor malignancy standard curative measure exist longer effective .</detailed_description>
	<criteria>Disease Related Histologically confirm advanced solid tumor refractory recurrent standard treatment . At least one site radiographically measurable disease ≥ 2 cm large dimension traditional compute tomography ( CT ) scan technique ≥ 1 cm large dimension spiral CT scanning ( per RECIST criterion ) ; , Principal Investigator 's opinion , evaluable disease reliably consistently follow , patient may eligible upon approval Onyx Therapeutics , Inc. , Medical Monitor . Demographic Males females ≥ 18 year age Life expectancy three month Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Laboratory Adequate hepatic function , bilirubin ≤ 1.5 time upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) ≤ 3 time ULN ≤ 5 time ULN presence hepatic tumor involvement Absolute neutrophil count ( ANC ) ≥ 1500/mm3 , hemoglobin ≥ 8 g/dL , platelet count ≥ 100,000/ mm3 1 . Screening platelet count must independent platelet transfusion least one week 2 . Screening ANC must independent granulocyte granulocyte/macrophage colony stimulate factor ( GCSF GMCSF ) support least one week pegylated GCSF least two week 3 . Patients may receive red blood cell ( RBC ) transfusion receive supportive care erythropoietin darbepoetin accordance institutional guideline Calculated measured creatinine clearance ≥ 30 mL/min ; calculation use generally accept formula Cockcroft Gault : CrCl = [ ( 140 Age ) × Mass ( kg ) / ( 72 × Creatinine mg/dL ) ] , multiply 0.85 female Ethical / Other Written inform consent accordance federal , local , institutional guideline Female patient childbearing potential must negative serum urine pregnancy test within three day first dose agree use dual method contraception study one month follow last dose study drug . Postmenopausal female ( &gt; 45 year old without menses &gt; 1 year ) surgically sterilize female exempt requirement . Male patient must use effective barrier method contraception study one month follow last dose sexually active female childbearing potential . Disease Related Chemotherapy approve investigational anticancer therapeutic , include steroid therapy , within four week prior first dose Oprozomib six week antibody therapy Radiation therapy immunotherapy within three week prior first dose ; localize radiation therapy within one week prior first dose Patients brain metastasis ( patient prior brain metastasis permit , must complete treatment evidence active CNS disease least three month prior first dose ) Prior treatment proteasome inhibitor Concurrent Conditions Major surgery within three week prior first dose Congestive heart failure ( New York Heart Association Class III IV ) , symptomatic ischemia , conduction abnormality . Conduction system abnormalities clinically warrant intervention allow . Myocardial infarction within three month prior first dose Active infection require systemic antibiotic , antiviral , antifungal within two week prior first dose HIV infection ( HIV seropositive ) Active hepatitis A , B , C infection Peripheral neuropathy Grade ≥ 3 Grade 2 pain time first dose Patients pleural effusion require repeat thoracentesis ascites require repeat paracentesis Prior Oprozomib therapy Hypersensitivity Oprozomib component Ethical / Other Female patient pregnant lactate Psychiatric medical condition opinion Investigator could interfere treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Solid Tumors</keyword>
</DOC>